Stock 603139 SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shaanxi Kanghui Pharmaceutical Co., Ltd. Stock

Equities

603139

CNE100002XT3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
12.77 CNY -2.30% Intraday chart for Shaanxi Kanghui Pharmaceutical Co., Ltd. -19.94% -31.97%
Mar. 15 Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback MT
2023 Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal MT

Financials

Sales 2021 443M 61.16M Sales 2022 492M 67.89M Capitalization 1.77B 245M
Net income 2021 36M 4.97M Net income 2022 -63M -8.7M EV / Sales 2021 5.3 x
Net Debt 2021 172M 23.75M Net Debt 2022 313M 43.24M EV / Sales 2022 4.24 x
P/E ratio 2021
58.8 x
P/E ratio 2022
-28.2 x
Employees 828
Yield 2021
0.34%
Yield 2022
-
Free-Float 39.72%
More Fundamentals * Assessed data

Chart Shaanxi Kanghui Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Shaanxi Kanghui Pharmaceutical Co., Ltd.

Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback MT
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership). CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million. CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd. CI
More news

Quotes and Performance

1 day-2.39%
1 week-18.06%
Current month-14.63%
1 month-14.13%
3 months-25.36%
6 months-34.02%
Current year-30.37%
More quotes

Highs and lows

1 week
12.03
Extreme 12.03
16.15
1 month
12.03
Extreme 12.03
17.61
Current year
8.81
Extreme 8.81
19.72
1 year
8.81
Extreme 8.81
21.60
3 years
8.81
Extreme 8.81
28.20
5 years
8.81
Extreme 8.81
28.20
10 years
8.81
Extreme 8.81
44.50
More quotes

Managers and Directors - Shaanxi Kanghui Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Yan Ling Wang CEO
 Chief Executive Officer 64 98-12-31
Bin Ze Zou DFI
 Director of Finance/CFO 37 18-12-10
Jin Yang BRD
 Director/Board Member 48 -
Members of the board TitleAgeSince
Jian Ping Hou BRD
 Director/Board Member 63 09-12-10
Yan Ling Wang CEO
 Chief Executive Officer 64 98-12-31
Jiang Hu BRD
 Director/Board Member 60 19-12-10
More insiders

Quotes

Date Price Change Volume
24-04-18 12.77 -2.30% 1 782 000
24-04-18 13.07 -2.39% 2,108,102
24-04-17 13.39 +3.32% 2,406,300
24-04-16 12.96 -10.00% 1,905,400
24-04-15 14.4 -10.00% 4,134,300

End-of-day quote Shanghai S.E., April 17, 2024

More quotes

Company Profile

SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. is principally engaged in research and development, manufacture and sales of Chinese patent medicines. The Company's main products include Kun Fu Kang capsules (tablets), Fufang Shuanghua tablets, Xiaoyin granules, Fuguigutong capsules, Zhiyao Xiaoke capsules and Fufang Qingdai perfusates. The Company distributes its products just within China domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-26 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
SHAANXI KANGHUI PHARMACEUTICAL CO., LTD. Stock Shaanxi Kanghui Pharmaceutical Co., Ltd.
-30.37% 180M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+20.91% 43.54B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.96% 21.74B
SANDOZ GROUP AG Stock Sandoz Group AG
+8.02% 13.53B
CIPLA LIMITED Stock Cipla Limited
+7.98% 13.02B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+33.80% 11.28B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.05% 6.99B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+7.71% 5.09B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603139 Stock